Pilot Study of Supervised Cardiac Rehabilitation for Adults with Cardiac Amyloidosis

What this Trial Is About

Researchers are studying cardiac amyloidosis, a condition affecting heart function, to evaluate how a supervised cardiac rehabilitation program might improve physical fitness and quality of life in patients with heart failure and preserved ejection fraction HFpEF. This pilot study aims to measure benefits of structured exercise in this higher risk population, potentially expanding access to rehabilitation for more cancer and non-cancer patients with cardiac issues. Participants are randomly assigned to either an intervention group or a control group. The intervention group undergoes baseline fitness tests including a 6-minute walk test and cardiopulmonary exercise test CPET, followed by a supervised cardiac rehabilitation program with three one-hour exercise sessions per week over 12 weeks, totaling 36 planned sessions. After completion, fitness tests are repeated within two weeks. The control group receives the same baseline and follow-up fitness tests 12 to 14 weeks apart without participating in the exercise program. During the study, participants complete fitness assessments to measure changes in cardiorespiratory fitness, including maximal oxygen uptake VO2, ventilatory efficiency, exercise capacity via walk tests, and quality of life using the Kansas City Cardiomyopathy Questionnaire KCCQ. Researchers also track how many participants complete at least 75% of the rehabilitation sessions. The study runs until December 2027, with participants monitored throughout the 12-week intervention or observation period.

CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study